RE:Drinking the wrong Koolaid with Phase 1 You must be new here. Biogen's market cap increased by about $40 billion after encouraging results from phase 1 for BIIB037 in 2015. That trial measured benefits (cognition) as well as safety. Might have been a phase 1b but definitely not a phase 2 or 3. I think at least a few would describe a $40 billion market cap increase as "exploded". All it takes is a couple of minutes to look up some information. You can try it yourself:
Expectations had been high ever since a Biogen executive told investors at a bank conference in Boston last December that aducanumab was showing a dose-dependent benefit on both amyloid removal and cognition.